



CORRECTING and REPLACING Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2019

CORRECTION...by Bioasis Technologies Inc.

October 25, 2019 05:44 PM Eastern Daylight Time

GUILFORD, Conn.--(BUSINESS WIRE)--First paragraph, first sentence of release should read: Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the "Company" or "Bioasis"), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB³™ platform technology for the delivery of therapeutics across the blood-brain barrier ("BBB") and the treatment of central nervous system ("CNS") disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced it has filed its unaudited financial statements and management's discussion and analysis for the period ended August 31, 2019 (instead of...today announced it has filed its audited annual financial statements and management's discussion and analysis for the period ended August 31, 2019).

The corrected release reads:

BIOASIS ANNOUNCES FILING OF ITS QUARTERLY FINANCIAL STATEMENTS AND MD&A FOR THE PERIOD ENDING AUGUST 31, 2019

Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the "Company" or "Bioasis"), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB³™ platform technology for the delivery of therapeutics across the blood-brain barrier ("BBB") and the treatment of central nervous system ("CNS") disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced it has filed its unaudited financial statements and management's discussion and analysis for the period ended August 31, 2019. All are available under the Company's profile on SEDAR at www.sedar.com and on the Company's website at www.bioasis.us/investors/.

ABOUT BIOASIS

Bioasis Technologies Inc. is a biopharmaceutical company developing the xB³™ platform, a proprietary technology for the delivery of therapeutics across the BBB and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The delivery of therapeutics across the BBB represents the final frontier in treating neurological disorders. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. The company maintains headquarters in Guilford, Conn., United States. Bioasis trades on the TSX Venture Exchange under the symbol "BTI" and on the OTCQB under the symbol "BIOAF." For more information about the company, please visit www.bioasis.us.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contacts

On behalf of the Board of Directors of Bioasis Technologies Inc.

Deborah Rathjen, Ph.D., Director and President & Chief Executive Officer

deborah@bioasis.us

+1 203 533 7082